1/29
08:03 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $30.00 price target on by analysts at Mizuho.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $30.00 price target on by analysts at Mizuho.
1/27
01:42 pm
crvs
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know [Yahoo! Finance]
1/25
08:01 pm
crvs
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study [Yahoo! Finance]
1/24
03:28 pm
crvs
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans [Yahoo! Finance]
Medium
Report
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans [Yahoo! Finance]
1/23
05:00 pm
crvs
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
Medium
Report
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
1/22
01:06 pm
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
1/22
01:11 am
crvs
Corvus Pharmaceuticals rises 5%, prices $175M stock offering at $22.15 [Seeking Alpha]
Medium
Report
Corvus Pharmaceuticals rises 5%, prices $175M stock offering at $22.15 [Seeking Alpha]
1/21
10:53 pm
crvs
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Medium
Report
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
1/21
02:51 pm
crvs
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon [Seeking Alpha]
Medium
Report
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon [Seeking Alpha]
1/21
11:44 am
crvs
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know [Seeking Alpha]
Low
Report
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know [Seeking Alpha]
1/21
10:11 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $32.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $32.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
1/20
04:06 pm
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
1/20
04:01 pm
crvs
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
1/20
02:02 pm
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $20.00 price target on by analysts at Mizuho.
Medium
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $20.00 price target on by analysts at Mizuho.
1/20
12:05 pm
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/20
07:00 am
crvs
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
High
Report
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
1/16
04:01 pm
crvs
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
High
Report
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
1/12
07:05 am
crvs
Retail investors account for 39% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while institutions account for 39% [Yahoo! Finance]
Low
Report
Retail investors account for 39% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while institutions account for 39% [Yahoo! Finance]
1/5
09:15 am
crvs
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference [Yahoo! Finance]
1/5
08:30 am
crvs
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
Medium
Report
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
12/11
10:04 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
12/8
10:30 am
crvs
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Medium
Report
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial